Clinical trial
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected…
NCT00354627 · Tibotec Pharmaceuticals, Ireland, Industry · Completed
Key facts
| NCT number | NCT00354627 |
|---|---|
| Title | The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs |
| Official title | Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV-1 |
| Intervention type | Drug |
| Interventions | TMC125 |
| Enrollment | 5,178 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Jul 20, 2006 |
| Last update posted | Jun 12, 2015 |
| Countries | Belgium, Canada, Denmark, Germany, Greece, Luxembourg, Mexico, Netherlands, Puerto Rico, Russia, South Korea, Spain and 4 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: